The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preliminary data from an ongoing phase IIb study of no carrier added 131I-iobenguane (nca-MIBG) in patients with malignant pheochromocytoma (Pheo).
D. A. Pryma
Research Funding - Molecular Insight Pharmaceuticals
J. A. Barrett
Employment or Leadership Position - Molecular Insight Pharmaceuticals
Stock Ownership - Molecular Insight Pharmaceuticals
R. E. Coleman
Honoraria - Molecular Insight Pharmaceuticals
Research Funding - Molecular Insight Pharmaceuticals
R. Noto
Research Funding - MolecularMD
C. Jimenez
Research Funding - Molecular Insight Pharmaceuticals
M. H. Pampaloni
Research Funding - Molecular Insight Pharmaceuticals
A. N. Serafini
Research Funding - Molecular Insight Pharmaceuticals
R. L. Wahl
Research Funding - Molecular Insight Pharmaceuticals
L. Kostakoglu
Research Funding - Molecular Insight Pharmaceuticals
N. D. LaFrance
Stock Ownership - Molecular Insight Pharmaceuticals
J. W. Babich
Employment or Leadership Position - Molecular Insight Pharmaceuticals